Qureight has announced the appointment of Craig Rhodes as head of partnerships to lead strategic engagements with pharmaceutical organisations, in line with Qureight’s revenue growth targets. Craig was formerly EMEA director of healthcare and life sciences at NVIDIA.
In his new role, Craig will lead on securing and managing strategic relationships with pharma partner organisations, from conception through to delivery. Leveraging his deep expertise in technology integration and relationship development, Craig will support the adoption and integration of the Qureight platform into clinical trial workflows. Qureight’s deep-learning image analysis and AI-powered data analytics platform enables real insights to be drawn from complex and diverse health data, including CT scans, physiological data and blood-based biomarkers to accelerate drug development and enhance outcomes for patients with lung and heart diseases, where there is high unmet medical need.
A highly experienced leader in AI across both big tech and the startup ecosystem, Craig has over 25 years of experience and a proven track record of driving innovation and transformation across the sector. In his role at NVIDIA, Craig’s leadership was instrumental to the accelerated adoption of AI in healthcare and drug discovery, notably through the operation of Cambridge-1, the UK’s largest AI supercomputer. This initiative enabled groundbreaking research and set a new benchmark for GPU-powered workloads in life sciences, with partners including GSK, AstraZeneca, King’s College London, Guy’s and St Thomas’ Hospital, and Oxford Nanopore. Craig joins Qureight from deepc, where he spearheaded strategic collaborations with the NHS to integrate AI imaging models into clinical workflows. Prior to his tenure at deepc, Craig played critical roles in driving pathology and genomics AI initiatives at Intel, developing national healthcare systems at Oracle, and contributing to clinical pathway design for the NHS at the map of medicine.
